Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion vs Escitalopram in MD with Inflammation and Anhedonia
NCT04352101Phase 4Completed
- Sponsor
- Emory University
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupropion in major depressive disorder (MDD), sponsored by Emory University. Primary endpoint: Ventromedial Prefrontal Cortex-Ventral Striatal Functional Connectivity at 8 weeks. Started Sep 2020; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04352101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352101.